John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.
John H. Sampson, MD, PhD, MBA, MHSc
Advertisement
Articles by John H. Sampson, MD, PhD, MBA, MHSc
Advertisement
Latest Updated Articles
Dr. Sampson on Nivolumab Monotherapy for Recurrent GlioblastomaPublished: November 20th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5